Literature DB >> 26077878

Prognosis of new-onset heart failure outpatients and collagen biomarkers.

Laura Sanchis1, Rut Andrea1, Carles Falces1, Jaume Llopis2, Manuel Morales-Ruiz3, Teresa López-Sobrino1, Félix Pérez-Villa1, Marta Sitges1, Manel Sabate1, Josep Brugada1.   

Abstract

BACKGROUND: Prognosis of heart failure patients has been defined in hospital-based or retrospective studies. This study aimed to characterize prognosis of outpatients with new-onset preserved or reduced ejection fraction heart failure; to explore the role of collagen turnover biomarkers (MMP2, MMP9, TIMP1) in predicting prognosis; and to analyse their relationship with echocardiographic parameters and final diagnosis.
METHODS: This is an observational, prospective, longitudinal study. Outpatients with new-onset heart failure symptoms referred to a one-stop clinic were included. Echocardiography and biomarkers plasma levels determination were performed at the inclusion. A prospective follow-up was conducted to report cardiovascular events. The discriminant analysis was applied to identify the parameters related to cardiovascular outcomes.
RESULTS: A total of 172 patients (75 ± 9 years) were included, 67% with heart failure (64% preserved and 36% with reduced ejection fraction). During follow-up (median 34.5 months), 32.6% had at least one cardiovascular event and 9.9% died. Heart failure groups showed no differences in cardiovascular outcomes with a higher rate of events than nonheart failure patients. MMP2 and TIMP1 were correlated with diastolic dysfunction (Rho 0.349 and 0.294, P < 0.001). In the discriminant analysis, the combination of biomarkers with clinical, biochemical and echocardiographic parameters was useful to predict cardiovascular outcomes (AUC ROC 0.806, Wilks lambda 0.7688, P < 0.001).
CONCLUSIONS: Prognosis of outpatients with new-onset heart failure symptoms is comparable between heart failure with preserved or reduced subgroups. The addition of biomarkers specially MMP2 and high sensitive troponin I to other clinical, biochemical and echocardiographic variables can predict cardiovascular prognosis at the time of diagnosis.
© 2015 Stichting European Society for Clinical Investigation Journal Foundation.

Entities:  

Keywords:  collagent turnover biomarkers; discriminant analysis; heart failure; heart failure with preserved left ventricular ejection fraction; outpantients; prognosis

Mesh:

Substances:

Year:  2015        PMID: 26077878     DOI: 10.1111/eci.12479

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  9 in total

Review 1.  Novel Biomarkers for the Risk Stratification of Heart Failure with Preserved Ejection Fraction.

Authors:  Jeremy Cypen; Tariq Ahmad; Jeffrey M Testani; Adam D DeVore
Journal:  Curr Heart Fail Rep       Date:  2017-10

Review 2.  Redefining biomarkers in heart failure.

Authors:  Michele Correale; Ilenia Monaco; Natale Daniele Brunetti; Matteo Di Biase; Marco Metra; Savina Nodari; Javed Butler; Mihi Gheorghiade
Journal:  Heart Fail Rev       Date:  2018-03       Impact factor: 4.214

Review 3.  Biomarkers in HFpEF for Diagnosis, Prognosis, and Biological Phenotyping.

Authors:  Moemen Eltelbany; Palak Shah; Christopher deFilippi
Journal:  Curr Heart Fail Rep       Date:  2022-10-05

4.  Ultra-high sensitivity cardiac troponin-I concentration and left ventricular structure and function in women with ischemia and no obstructive coronary artery disease.

Authors:  Odayme Quesada; Omeed Elboudwarej; Michael D Nelson; Ahmed Al-Badri; Mitra Mastali; Janet Wei; Bijan Zarrabi; Nissi Suppogu; Haider Aldiwani; Puja Mehta; Chrisandra Shufelt; Galen Cook-Wiens; Daniel S Berman; Louise E J Thomson; Eileen Handberg; Carl J Pepine; Jennifer E Van Eyk; C Noel Bairey Merz
Journal:  Am Heart J Plus       Date:  2022-03-03

5.  Physical versus psychological social stress in male rats reveals distinct cardiovascular, inflammatory and behavioral consequences.

Authors:  Julie E Finnell; Calliandra M Lombard; Akhila R Padi; Casey M Moffitt; L Britt Wilson; Christopher S Wood; Susan K Wood
Journal:  PLoS One       Date:  2017-02-27       Impact factor: 3.240

6.  Serum Matrix Metalloproteinases and Left Atrial Remodeling-The Hoorn Study.

Authors:  Pauline B C Linssen; Hans-Peter Brunner-La Rocca; Casper G Schalkwijk; Joline W J Beulens; Petra J M Elders; Amber A van der Heijden; Roderick C Slieker; Coen D A Stehouwer; Ronald M A Henry
Journal:  Int J Mol Sci       Date:  2020-07-13       Impact factor: 5.923

7.  Prognostic Value of Serum Galectin-3 in Chronic Heart Failure: A Meta-Analysis.

Authors:  Zhendong Cheng; Kefeng Cai; Chaoxian Xu; Qiong Zhan; Xingbo Xu; Dingli Xu; Qingchun Zeng
Journal:  Front Cardiovasc Med       Date:  2022-02-18

8.  Relationship of polymorphisms in the tissue inhibitor of metalloproteinase (TIMP)-1 and -2 genes with chronic heart failure.

Authors:  Evelise Regina Polina; Raquel Rosa Candebat Vallejo Araújo; Renan Cesar Sbruzzi; Andréia Biolo; Luís Eduardo Rohde; Nadine Clausell; Kátia Gonçalves Dos Santos
Journal:  Sci Rep       Date:  2018-06-21       Impact factor: 4.379

9.  Identification of Potential Gene Interactions in Heart Failure Caused by Idiopathic Dilated Cardiomyopathy.

Authors:  Huijuan Huang; Beibei Luo; Boqun Wang; Qianwen Wu; Yuming Liang; Yan He
Journal:  Med Sci Monit       Date:  2018-10-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.